K
Kezar Life Sciences, Inc. (KZR)
6.20
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
6.20
0.00 (0.00%)
Kezar Life Sciences, Inc., klinik tadqiqot bosqichidagi biotexnologiya kompaniyasi, Qo'shma Shtatlarda immun vositali kasalliklarda qondirilmagan ehtiyojlarni davolash uchun yangi kichik molekulali terapevtik vositalarni kashf qilish va ishlab chiqish bilan shug'ullanadi. Kompaniyaning etakchi dori nomzodi zetomipzomib (KZR-616), turli ko'rsatmalarga, shu jumladan lupus nefropatiyasi, dermatomiyozit va polimiozit; hamda tizimli qizil yug'irich kasalligida 1b/2 fazali klinik tadqiqotlar uchun tanlangan immunoproteasoma inhibitordir. Kompaniya, shuningdek, an'anaviy kimyoterapiya vositalariga chidamli o'smalarni davolash uchun birinchi o'z sinfidagi oqsil sekretsiyasining yangi ingibitori bo'lgan KZR-261ni ishlab chiqmoqda. Kezar Life Sciences, Inc. 2015 yilda tashkil etilgan va shtab-kvartirasi Kaliforniyaning Janubiy San-Fransisko shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Christopher J. Kirk Ph.D. | Co-Founder, CEO & Director |
| Dr. Jack Taunton Ph.D. | Co-Founder |
| Mr. John Franklin Fowler | Co-Founder & Director |
| Mr. Marc L. Belsky CPA | CFO & Secretary |
| Mr. Mark Schiller | Chief Operations Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-12 | 8-K | kzr-20260306.htm |
| 2025-11-12 | 8-K | kzr-20251112.htm |
| 2025-11-07 | 8-K | kzr-20251106.htm |
| 2025-10-22 | 8-K | kzr-20251020.htm |
| 2025-10-16 | 8-K | kzr-20251016.htm |
| 2025-08-13 | 10-Q | kzr-20250630.htm |
| 2025-06-23 | 8-K | kzr-20250617.htm |
| 2025-05-13 | 10-Q | kzr-20250331.htm |
| 2025-04-25 | ARS | a2025formars.pdf |
| 2025-04-01 | 8-K | kzr-20250327.htm |